2. Academic Validation
  3. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases

Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases

  • ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011.
Ram W Sabnis 1
Affiliations

Affiliation

  • 1 Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
PMID: 38352847 DOI: 10.1021/acsmedchemlett.4c00011
Abstract

Provided herein are novel fused triazole compounds as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating neurodegenerative, autoimmune, and inflammatory diseases, and processes for preparing such compounds.

Figures
Products